Indiana University Health University Hospital
Indiana University Health University Hospital
Indianapolis, Indiana, United States28 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) | Chronic Disease, Disease Attributes, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bronchial disorder, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, pulmonary emphysema, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 2 | 2026-10-08 | NCT07759245 | |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07174336 | |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-08 | NCT07165028 | |
| Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Body Weight, Crohn disease, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-07 | NCT06937099 | |
| Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Body Weight, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, nutritional disorder, obesity disorder, overnutrition, ulcerative colitis | Recruiting | Phase 3 | 2026-10-07 | NCT06937086 | |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Recruiting | Phase 2 | 2026-10-06 | NCT05039619 | |
| Sacrum Pressure Injury Prevention Study Using ALLEVYN◊ Complete Care in Adults at Risk of Developing Hospital-acquired Pressure Injuries in Critical Care Units | Skin Ulcer, Skin and Connective Tissue Diseases, decubitus ulcer, skin disorder | Not yet recruiting | Not applicable | 2026-09-30 | NCT07849387 | |
| VE303 for Prevention of Recurrent Clostridioides Difficile Infection | Bacterial Infections and Mycoses, Clostridium difficile Infections, Clostridium difficile colitis, Clostridium infectious disease, Digestive System Diseases, Infections, bacterial infectious disease, central diabetes insipidus, digestive system disorder, dysentery, gastroenteritis, gram-positive bacterial infections, intestinal disorder | Recruiting | Phase 3 | 2026-09-29 | NCT06237452 | |
| Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 4 | 2026-09-25 | NCT06952660 | |
| A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Body Weight, Body Weight Changes, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Gain, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-24 | NCT06439277 | |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT06712316 | |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | Phase 3 | 2026-09-17 | NCT07217717 | |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-09-17 | NCT07217704 | |
| A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease | Moderately to Severely Active Crohns Disease | Recruiting | Phase 3 | 2026-09-16 | NCT06819878 | |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-09-15 | NCT06215118 | |
| A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | Moderately to Severely Active Ulcerative Colitis | Active, not recruiting | Phase 3 | 2026-09-14 | NCT06589986 | |
| The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM | Digestive System Diseases, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, digestive system disorder, gastroparesis, palsy, stomach disorder | Recruiting | Not applicable | 2026-09-08 | NCT06493032 | |
| A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT04232553 | |
| A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis | Digestive System Diseases, acute pancreatitis, pancreas disorder, pancreatitis | Recruiting | Phase 2 | 2026-08-05 | NCT06080789 | |
| Pilot Trial for WounDx™ Clinical Decision Support Tool | Wounds, injury | Recruiting | Not applicable | 2026-07-30 | NCT06921707 | |
| Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hypercalciuria, Hypercalciuric Hypocalcemia, Familial, Hypocalcemia, Male Urogenital Diseases, Musculoskeletal Abnormalities, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, Water-Electrolyte Imbalance, calcinosis, calcium metabolic disease, endocrine system disorder, hypoparathyroidism, kidney disorder, metabolic disease, muscle tissue disorder, musculoskeletal system disorder, nephrocalcinosis, nephrolithiasis, nervous system disorder, neuromuscular disease, parathyroid gland disorder, urinary system disorder, urolithiasis | Active, not recruiting | Phase 3 | 2026-07-29 | NCT05680818 | |
| Indiana University Gastrointestinal Motility Diagnosis Registry | Deglutition Disorders, Digestive System Diseases, Eosinophilia, Fecal Incontinence, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, Vomiting, chronic intestinal pseudoobstruction, colonic disorder, constipation disorder, digestive system disorder, dyskinesia of esophagus, eosinophilic esophagitis, esophageal disorder, esophagitis, functional colonic disease, gastroenteritis, gastroesophageal reflux disease, gastroparesis, hematologic disorder, immune system disorder, intestinal disorder, irritable bowel syndrome, leukocyte disorder, palsy, rectal disorder, small intestinal bacterial overgrowth, stomach disorder | Recruiting | Not stated | 2026-06-16 | NCT04506593 | |
| Esophageal Impedance and Manometry Measurements and Dysphagia Symptom Scoring | Deglutition Disorders, Digestive System Diseases, Esophageal Dysphagia, Pharyngeal Diseases, digestive system disorder, esophageal disorder, otorhinolaryngologic disease | Recruiting | Not stated | 2026-06-16 | NCT04503785 | |
| A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 1 diabetes mellitus | Active, not recruiting | Phase 3 | 2026-05-12 | NCT06914895 | |
| A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 3 | 2026-04-20 | NCT03519945 |